Adam Testro

Prof. Dr. Adam Testro


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2009 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
ATAdam Testro
Adam Testro
KVKumar Visvanathan
Kumar Visvanathan

24 September 2007 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
JLJ. S. Lubel
J. S. Lubel
ATAdam Testro
Adam Testro
PAP. W. Angus
P. W. Angus

1 February 2013 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
JTJason A. Trubiano
Jason A. Trubiano
BGBradley Gardiner
Bradley Gardiner
JKJason C. Kwong
Jason C. Kwong
PWPeter Ward
Peter Ward
ATAdam Testro
Adam Testro
PCPatrick G.P. Charles
Patrick G.P. Charles
We describe a case of faecal microbiota transplantation (FMT) used for severe binary toxin-positive Clostridium difficile infection in an intensive care setting. The patient was admitted to the ICU of a tertiary hospital and failed traditional maximal pharmacological management. Adjunctive therapy with FMT given through gastroscopy resulted in resolution of the C. difficile-related symptoms. Although there is a growing experience with FMT for recurrent C. difficile infection, published evidence in severe disease is very limited. In a landscape of increasingly severe C. difficile infection, adjunctive FMT may be considered a useful early treatment option.

1 January 2014 in World Journal of Transplantation
Verified
Journal Article
Open access
SSSiddharth Sood
Siddharth Sood
ATAdam Testro
Adam Testro
Many of the causes of short and late morbidity following liver transplantation are associated with immunosuppression or immunosuppressive medications. Current care often involves close monitoring of liver biochemistry as well as therapeutic drug levels. However, the postoperative course following liver transplantation can often be associated with significant complications including infection and rejection, suggesting an inadequacy in current immune function monitoring. Many assays have been tested in the research setting to identify possible biomarkers that may be used to predict clinical events such as acute cellular rejection, and therefore allow modification of a patient's immunosuppressive regimen prior to a clinical event. However, these generally require significant laboratory processing and have had difficulty becoming established in common clinical use outside the research setting. One assay, Cylex ImmuKnow has been food and drug administration approved but has had variable results. In this review we discuss the assays that have been used to assess monitoring of immune function after liver transplantation and consider possible future directions.

17 February 2022 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
BCBrooke Chapman
Brooke Chapman
SGSu Kah Goh
Su Kah Goh
FPFrank Parker
Frank Parker
SRSarah Romero
Sarah Romero
MSMarie Sinclair
Marie Sinclair
ATAdam Testro
Adam Testro

22 December 2010 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
ATAdam Testro
Adam Testro
KVKumar Visvanathan
Kumar Visvanathan
NSNarelle Skinner
Narelle Skinner
VMVesna Markovska
Vesna Markovska
PCPeter Crowley
Peter Crowley
PGPaul J Gow
Paul J Gow